SCHEMBL6085102

SCHEMBL6085102

COc1cc(OC)c(CC(=O)Nc2ccc(-c3n[nH]cc3-c3nc4ccc(C)cc4o3)cc2)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
POLB P06746 3/20 0.54
CETP P11597 2/20 0.53
RXFP1 Q9HBX9 2/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 4/20 0.46
USP2 O75604 3/20 0.46
MEN1 O00255 2/20 0.46
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.46
PPARG P37231 1/20 0.46
NCOA2 Q15596 1/20 0.46
NCOA1 Q15788 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TP53 P04637 4/20 0.46
THRB P10828 1/20 0.46
CEPT1 Q9Y6K0 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085409 0.90 MAPT (0.55) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6086486 0.84 MAPT (0.51) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6084339 0.82 P2RY14 (0.51) MAPTSMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL6085234 0.82 MAPT (0.57) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6085354 0.81 MAPT (0.51) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6085381 0.80 CETP (0.56) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6085906 0.80 MAPT (0.53) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6086379 0.79 CETP (0.40) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6084754 0.78 MAPT (0.67) MAPTSMN1; SMN2POLBCETPRXFP1
SCHEMBL6084603 0.78 CETP (0.64) MAPTSMN1; SMN2POLBCETPRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885SMN1; SMN2 831/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.